INCYClinical•businesswire•
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
Sentiment:Positive (80)
Summary
WILMINGTON, Del.--(BUSINESS WIRE)--Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 12, 2025 by businesswire